Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2016

View Archived Issues

Novel benzylpyrazole-based BUB1 kinase inhibitors with antitumor activity

INCB-059872 demonstrates promising in vitro and in vivo activity in models of AML

Graybug Vision closes series B financing to further develop AMD drug

City of Hope licenses gene editing technology to new company Homology Medicines

PHSA and University of British Columbia patent labeled compounds for cancer diagnosis

Sage Therapeutics discloses GABA receptor modulators

Phase II dose of bispecific antibody MCLA-128 defined in first-in-human solid tumor study

FDA grants fast track status to Axsome Therapeutics' AXS-02

MYK-461 granted FDA orphan status for symptomatic obstructive hypertrophic cardiomyopathy

Juno's JCAR-017 receives diffuse large B-cell lymphoma orphan designation

GlaxoSmithKline quadrivalent influenza vaccine safe, immunogenic in children under 3 years old

FDA grants priority review to Blincyto sBLA for pediatric Ph-negative B-cell precursor ALL

BioNovus Innovations and University of Kansas Medical Center's IAMI form partnership

Ischemix's phase II CARIN trial misses prespecified endpoints

Bayer describes novel radioimmunoconjugate BAY-1862864 entering phase I development

Biogen to spin off hemophilia business

pSivida's Medidur wins orphan medicinal product designation in Europe

TG Therapeutics begins phase II study of ublituximab in MS

Triphase Accelerator and Celgene expand marizomib collaboration

EMA grants accelerated assessment to cerliponase alfa MAA

Marina Biotech to acquire Turing's phase III intranasal ketamine program

Santhera Pharmaceuticals preparing NDA, MAA for Raxone in DMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...